Aquestive Therapeutics (NASDAQ:AQST) Receives Buy Rating from HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 82.15% from the stock’s current price.

AQST has been the subject of several other reports. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Leerink Partners reiterated an “outperform” rating and issued a $12.00 target price (up previously from $10.00) on shares of Aquestive Therapeutics in a research note on Monday, September 30th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $8.83.

Aquestive Therapeutics Stock Up 0.2 %

NASDAQ:AQST opened at $5.49 on Friday. The company has a market cap of $499.80 million, a P/E ratio of -13.07 and a beta of 2.85. The firm’s 50 day moving average is $4.77 and its two-hundred day moving average is $3.76. Aquestive Therapeutics has a fifty-two week low of $1.37 and a fifty-two week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.08. The firm had revenue of $20.10 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same period last year, the business posted ($0.10) earnings per share. Research analysts forecast that Aquestive Therapeutics will post -0.48 earnings per share for the current fiscal year.

Institutional Trading of Aquestive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. acquired a new stake in Aquestive Therapeutics during the 2nd quarter valued at approximately $27,000. nVerses Capital LLC acquired a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at approximately $28,000. SG Americas Securities LLC purchased a new position in shares of Aquestive Therapeutics during the 1st quarter valued at approximately $54,000. The Manufacturers Life Insurance Company purchased a new position in shares of Aquestive Therapeutics during the 2nd quarter valued at approximately $76,000. Finally, Financial Advocates Investment Management grew its position in shares of Aquestive Therapeutics by 70.0% during the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after buying an additional 14,000 shares in the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.